Metabolomic Diagnostics’ Post

Survival without severe neonatal morbidity after antenatal betamethasone dose reduction: a post hoc analysis of a randomized non-inferiority trial - Distribution of the number and types of severe cumulative morbidities among infants born before 32 weeks of gestation https://ow.ly/GCwa50Tsh14

We're sharing new data in #achondroplasia and other growth-related conditions at the Pediatric Endocrine Society meeting this weekend. Learn more: https://bit.ly/4b4VU1Q #PedsEndo2024

Survival without severe neonatal morbidity after antenatal betamethasone dose reduction: a post hoc analysis of a randomized non-inferiority trial - Survival without severe neonatal morbidity among infants born before 32 weeks of gestation and in prespecified subgroups https://ow.ly/GCwa50Tsh14

Over the past decade, there's been a notable surge in anticoagulation therapies for pediatric patients, with up to 15% of hospitalized children benefiting from #heparin or heparinoids. Frequent monitoring of Anti Factor Xa activity (aFXa) is crucial for children on heparin therapy, sometimes up to 2-3 times per day, to maintain therapeutic levels. However, current tests often require large blood volumes, posing a risk of iatrogenic anemia in neonates. Read this interesting blog on the "Unique Challenges to Heparin Monitoring in Neonatal and Pediatric Populations" and how Baebies' #DigitalMicrofluidics (#DMF) technology is addressing this challenge using only ~50 µL whole blood input with ~14 minutes time to result. Such a test would enable pediatric heparin therapy management, providing clinicians with timely data. Link: https://lnkd.in/gV4qvQEz #AnytestAnywhereEveryone #Heparin

Embark on a journey of groundbreaking innovation with First Breath Health Pty Ltd,a pioneering force in early asthma detection. In a world where childhood asthma rates soar and prenatal tests are scarce, First Breath steps in to revolutionize pediatric care. Their cutting-edge asthma test, boasting an unprecedented 72% accuracy in identifying at-risk children before birth, marks a monumental leap in medical advancement. By challenging conventional diagnostic practices, First Breath opens doors to early detection, potentially reshaping the trajectory of pediatric care before the age of 5. With a commitment to empowering parents through proactive tools, including a newly launched book packed with recommendations and interventions, First Breath aims to mitigate asthma risks for both mother and baby. Now, on the brink of transformative change, First Breath seeks private investment to fuel its mission of fostering healthier futures for generations to come Deborah Kennedy #channel9 #Guruproductions #9NOW #innovation #JTSI

Metformin has been linked to reduced hospitalizations in children diagnosed with asthma, as highlighted in a recent study. This finding underscores the potential benefits of Metformin in managing asthma-related health outcomes. The research suggests that incorporating Metformin into treatment regimens for pediatric asthma patients may lead to a decrease in hospital admissions. This insight sheds light on the importance of exploring alternative treatment options for asthma management in children. #Metformin #AsthmaManagement

Multiple pediatric #ECMO runs: what are the limits? 🔍 single pediatric center, 2010-23 🔎 13% children required multiple runs; use of multiple runs increased within study period 🪦 mortality 80% before discharge; late 89%: significantly higher vs single runs 🧠 67% neurologic complication; 1% normal neurodevelopment at followup. All patients with neurologic findings before second run died: this should be taken into consideration considering an additional run 🚧 duration of first run, total time on #ECLS, neurologic findings at any time, need for #RRT, lactate correlated with late mortality. Carefully discuss risks & benefits before considering; shorter/fewer runs could provide a more compassionate approach for families facing desperate situations ASAIO Journal 🔗 https://bit.ly/3BUHBjV

An important paper on the Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023) by Bradford L. Therrell, et al. Int. J. Neonatal Screen. 2024, 10(2), 38; https://lnkd.in/dRUWdNW6 - An excellent state of the art to plan future action plans.

Our Phase 2 data is now live in NEJM Group (New England Journal of Medicine), building on a growing body of data behind our investigational treatment for pregnant individuals at high risk of hemolytic disease of the fetus and newborn (HDFN), a rare and serious condition that affects pregnant individuals and their babies.    This is a testament to our continued focus on developing treatments for auto- and alloantibody driven diseases and driving progress in maternal fetal medicine. Tarek Ebrahim, M.D. Aimee Amann, MBA Yosuke Komatsu, MD, PhD, FACOG, FJSOG, FJSUM Marie Fitzgibbon Bridget Kimmel Carol Mao Sheryl Pease, MBA PMP Wim Noel Lisa Shea Jannine Williams John Yeomans Prasheen Agarwal 🟦🎗️Andreia Naomi Pierce, PhD MBA Kelly Fitzsimmons Edwin Lam Jocelyn H. Leu, Pharm.D./Ph.D. Steve Calabro, MS, MBA   #JNJImmunology #MyCompany, #HDFN

Indications affect neonatal outcomes following early rescue ICSI: a retrospective study https://lnkd.in/dhHbe5VE